FDA’s Pharmacy Compounding Advisory Committee voted on July 23 and 24, 2026 to recommend six peptides for the 503A bulks list. Those votes are advice. As of October 9, 2026, none of the six is on the list in 21 CFR 216.23, none sits in FDA’s Category 1, and a 503A pharmacy has no federal pathway to compound any of them. A news report about a temporary stopgap does not change that.
The committee said yes to six and FDA staff said no to all seven
The committee reviewed seven peptides, each in a free base and an acetate form. FDA’s own briefing document proposed, for every one of the 14 substances, that it “NOT be included on the 503A Bulks List.” The committee disagreed on six.
| Peptide | Committee vote (yes-no-abstain) | FDA staff recommendation | Status as of October 9, 2026 |
|---|---|---|---|
| BPC-157 | 8-6-1 | Do not include | Not on 503A list, not in Category 1 |
| KPV | 8-6-1 | Do not include | Not on 503A list, not in Category 1 |
| TB-500 | 8-6-1 | Do not include | Not on 503A list, not in Category 1 |
| MOTS-c | 7-5-2 | Do not include | Not on 503A list, not in Category 1 |
| Semax | Recommended; reported as 8-5-1 | Do not include | Not on 503A list, not in Category 1 |
| Epitalon | Recommended; reported as 7-4-1 or 7-5-1 | Do not include | Not on 503A list, not in Category 1 |
| Emideltide (DSIP) | Not recommended; reported as 6-7-1 | Do not include | Not on 503A list, not in Category 1 |
Tallies come from trade press and a law firm summary of the public meeting; FDA had not posted minutes on the meeting page when we checked. Reports disagree on the Epitalon count. Status comes from the eCFR text of 21 CFR 216.23 as of October 1, 2026 and FDA’s category list updated May 14, 2026, where none of these peptides appears. Our peptide status tracker carries the per-compound detail.
Both sides made real arguments
Supporters on the committee framed it as a question of who decides. One member who voted yes on BPC-157 said, as reported by RAPS, “it’s time to put this decision back in the hands of the physician and pharmacist.” Another, voting yes on Epitalon, said a physician and pharmacist are key to judging the risk for an individual patient. A law firm summary of the meeting reports that some yes votes came with conditions: authorized API sourcing, adverse event reporting and formulation requirements.
The access argument is about where patients already are. NPR reported in July 2026 that restrictions pushed these peptides into a gray market, and quoted a pharmacist who represents peptide makers saying the restrictions “opened up a gray and black market” and that patients should have “the safest route available.” The Alliance for Pharmacy Compounding has asked FDA “to use interim enforcement discretion to permit patient-specific compounding of selected peptides” under conditions that include “validated sourcing of cGMP-compliant active ingredients,” USP-compliant preparation, enhanced patient disclosures and serious adverse event reporting.
FDA staff’s concerns are specific. In the BPC-157 evaluation, reviewers found the substance “not well-characterized” for identity, purity and quality, flagged “the potential for immunogenicity” in injectable form from aggregation and peptide-related impurities, found “no studies that administered BPC-157 to humans” by the subcutaneous, oral, nasal or transdermal routes, and concluded the data “do not support the use of BPC-157” for ulcerative colitis, the use under review. Members who voted no echoed this. RAPS reported one citing the “lack of efficacy data and randomized controlled trials.”
A vote does not create a 503A pathway
Section 503A lets a pharmacy compound from a bulk substance only if it has a USP or NF monograph, is a component of an FDA-approved drug, or appears on the list FDA builds “through regulations.” That list is 21 CFR 216.23(a). Getting a peptide onto it takes three steps:
- FDA decides whether to accept the advice. The briefing document says FDA “does not intend to issue a final determination” until the committee’s input is considered and reviews are final.
- FDA publishes a proposed rule in the Federal Register and opens a comment period.
- FDA publishes a final rule amending 216.23. Only then is the substance lawful bulk material for 503A compounding.
That path can be slow. FDA proposed adding five substances to the list in September 2019. As of October 1, 2026, the eCFR still shows the same six substances placed there by the February 2019 final rule. A listing would also not make any peptide FDA approved, and 216.23(d) states there are inadequate data to show the safety or efficacy of products compounded from listed substances.
Enforcement discretion leaves the statute where it is
Enforcement discretion means FDA chooses not to pursue a violation it could pursue. The statute stays the same. FDA has used it for bulk substances before. Its guidance, “Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A,” describes conditions under which FDA “does not intend to take action” against compounders using substances in Category 1 while the list is built. The January 7, 2025 version (90 FR 1136) states that it “is not binding on FDA or the public,” ends categorization for substances nominated on or after that date, and lets FDA remove a substance from Category 1 based on, for example, safety risks.
Two points follow. First, discretion has conditions; FDA’s 503A page says bulk substances must come with a valid certificate of analysis from an FDA-registered establishment. Second, it can be withdrawn without rulemaking, and it binds only FDA. Your state board of pharmacy and medical board apply their own rules regardless.
What the October 7 report says, and what it leaves open
The Washington Post reported on October 7, 2026, citing two people familiar with the matter, that the administration is crafting plans to allow temporary sale of some previously restricted peptides while rules are developed. The plan has not been announced. The report does not say which peptides, and the Alliance for Pharmacy Compounding notes “there is no announced timeline.”
Read it against the framework above. FDA’s current interim policy covers only Category 1 substances, and none of these six is in Category 1. So any stopgap would need a new FDA document, such as revised guidance or a category change. If it arrives, it would likely tell 503A pharmacies when FDA will not act. It would not put a peptide on 216.23, would not make it approved, would not cover research-use-only material (see why that label is no shield), and would not override state law. How it treats 503B outsourcing facilities is unknown; the 503A and 503B rules differ.
What this means for you
Do not change your menu on a news report. Wait for a Federal Register notice or an FDA guidance document, then read its conditions: which substances, which forms and routes, which sourcing documentation, and whether it reaches your pharmacy type. Ask your pharmacy, in writing, how it will meet those conditions before you prescribe. Our providers do not prescribe any peptide without a lawful pathway, and we will update peptide compounding status the day FDA publishes. If you are planning a peptide program around a possible change, book a call and we will map it with you.
Frequently asked questions
Are BPC-157 and TB-500 legal to compound now that the FDA panel voted yes?
No. As of October 9, 2026, neither is on the 503A bulks list in 21 CFR 216.23, and neither is in FDA’s Category 1. The July 2026 votes were advisory. FDA must decide whether to accept them and then complete notice-and-comment rulemaking before a 503A pharmacy has a federal pathway to compound either peptide.
How long does it take FDA to add a substance to the 503A bulks list?
There is no fixed deadline. FDA must publish a proposed rule, take comments and publish a final rule. History suggests patience: FDA proposed five additions in September 2019, and as of October 1, 2026 the list still contains only the six substances placed there by the February 2019 final rule.
What would a temporary sale policy for peptides actually allow?
No policy has been announced, so nobody knows. The Washington Post reported a plan on October 7, 2026, citing two unnamed sources. If FDA issues one, it would likely be enforcement discretion: a statement that FDA will not act against compounders who meet set conditions. It would not approve any peptide or change state law.
Does FDA enforcement discretion protect my clinic under state law?
No. Enforcement discretion is FDA’s decision about its own enforcement, and FDA’s guidance says it is not binding on FDA or the public. Your state board of pharmacy and medical board apply their own rules. Confirm your state’s position, and your pharmacy’s, before you prescribe any peptide that a federal stopgap covers.
This is general information, not legal advice. Rules vary by state and change. Confirm your own facts with counsel.